All In Biotech

Drug Trial Radar · NCT01376297

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 413 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

413

Actual

Start

Jul 2011

Primary completion

Sep 2012

Sponsor

Lead sponsor
Helsinn Healthcare SAIndustry
Sponsor type
Industry
Collaborators
Parexel
First posted
Jun 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.

Conditions

  • Chemotherapy-Induced Nausea and Vomiting

Interventions

  • Netupitant and PalonosetronDrug

  • AprepitantDrug

  • PalonosetronDrug

  • DexamethasoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Adverse EventsTime frame: Participants will be followed for the duration of the chemotherapy, an expected average duration of up to 24 weeks assuming 6 chemotherapy cycles given every 4 weeks

Locations

75 sites in 10 countries. Site status is shown where the registry gives one.

  • Northwest Alabama Cancer Center PC

    Muscle Shoals, Alabama

  • East Valley Hematology and Oncology Medical Group

    Burbank, California

  • American Institute of Research

    Los Angeles, California

  • Veterans Administration New Jersey Health Care System

    East Orange, New Jersey

  • Hematology Oncology Associates of Rockland

    Nyack, New York

  • Hematology and Oncology Associates, Inc.

    Canton, Ohio

  • Tri-County Hematology & Oncology Associates, Inc

    Massillon, Ohio

  • Cancer Center at Memorial Hospital of RI

    Pawtucket, Rhode Island

  • Spartanburg Regional Health Services

    Spartanburg, South Carolina

  • South Texas Comrehensive Cancer Centers

    Corpus Christi, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • UMHAT "Dr. Georgi Stranski"

    Pleven, Bulgaria

  • Complex Oncology Center - Shumen Ltd. [Oncology]

    Shumen, Bulgaria

  • Specialized Hospital for Active Treatment in Oncology "Dr. Marko Markov" Varna

    Varna, Bulgaria

  • COC - Veliko Tarnovo Dept. Medical Oncology

    Veliko Tarnovo, Bulgaria

  • COC - Vratsa Dept. of Palliative Care

    Vratsa, Bulgaria

  • Oblastni nemocnice Mlada Boleslav a.s., Onkologie

    Mladá Boleslav, Czechia

  • AVICENNUS s.r.o. Onkologie Nymburk

    Nymburk, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Nemocnice Na Homolce, Oddeleni klinicke onkologie

    Prague, Czechia

  • Nemocnice Znojmo, p.o.

    Znojmo, Czechia

  • Gemeinschaftspraxis, Dr. Med O.Brundler und B.Heinreich, PD Dr. med M.Bangerter Fachärzte für Innere Medizin, Hämatologie und internistische Onkologie

    Augsburg, Germany

  • Charite - Campus Benjamin Franklin (CBF)

    Berlin, Germany

  • Medizinisches Versorgungszentrum für Hämatologie und Tumorerkrankungen, HIV/AIDS und Hepatitiden

    Berlin, Germany

  • Universitaetsklinikum Carl Gustav Carus

    Dresden, Germany

  • St. Johannes Hospital Medizinische Klinik II, Hämatologie, Onkologie und klinische Immunologie

    Duisburg, Germany

  • Praxis Fuer Interdisziplinaere Onkologie und Haematologie

    Freiburg im Breisgau, Germany

  • Medizinische Hochschule, Zentrum für Innere Medizin, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation

    Hanover, Germany

  • Ärzteforum Hennigsdorf

    Hennigsdorf, Germany

  • Praxis für Innere Medizin, Hämatologie und Internistische Onkologie

    Marburg, Germany

  • Krankenhaus, Maria Hilf, St. Franziskus Innere Medizin

    Mönchengladbach, Germany

  • OncoPRO GbR Dr. R. Dengler, Dr. A. Kröber

    Regensburg, Germany

  • Országos Onkológiai Intézet, B. Belgyógyászati Osztály

    Budapest, Hungary

  • Bekes Megyei Kepviselo-testulet Pandy Kalman Korhaz

    Gyula, Hungary

  • Kaposi Mor Oktato Korhaz [Klinikai Onkologiai Centrum]

    Kaposvár, Hungary

  • Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktatók

    Miskolc, Hungary

  • Fejér Megyei Szent György Kórház [Onkológiai Osztály]

    Székesfehérvár, Hungary

  • Dr. Bugyi Istvan Korhaz [Oncology]

    Szentes, Hungary

  • Kumaran Hospital PVT Ltd

    Chennai, India

  • Dr.Rai Memorial Medical centre

    Chennai, India

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.